ESR1 and breast carcinoma: In contrast, monitoring the evolution of circulating cellular subpopulations may provide a readout of response/resistance to treatment, such as the proportion of circulating cancer-derived cells in breast cancer that express or contain the estrogen receptor (ER) or overexpress human epidermal growth factor-receptor 2 (HER2) in breast cancer, both of which are therapeutic targets.